- Home
- UPST vs APGE Comparison
UPST vs APGE Comparison
Compare UPST & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UPST | APGE |
|---|---|---|
| Founded | 2012 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.7B |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | UPST | APGE |
|---|---|---|
| Price | $28.14 | $71.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 10 |
| Target Price | $46.82 | ★ $103.33 |
| AVG Volume (30 Days) | ★ 5.4M | 859.5K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 131.25 | 1.79 |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $1,043,857,000.00 | N/A |
| Revenue This Year | $34.07 | N/A |
| Revenue Next Year | $31.97 | N/A |
| P/E Ratio | $60.53 | ★ N/A |
| Revenue Growth | ★ 63.99 | N/A |
| 52 Week Low | $27.04 | $26.20 |
| 52 Week High | $85.31 | $84.56 |
Technical Indicators
Market Signals| Indicator | UPST | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 26.30 | 48.32 |
| Support Level | N/A | $35.24 |
| Resistance Level | $50.78 | $71.18 |
| Average True Range (ATR) | 2.36 | 3.57 |
| MACD | -0.63 | 0.64 |
| Stochastic Oscillator | 5.19 | 79.96 |
Price Performance
Historical ComparisonAbout UPST Upstart Holdings Inc.
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit, and small-dollar loans.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.